AKTIS ONCOLOGY TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Cambridge, MASS. (January 6, 2022) – Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers, today announced the company will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference, taking place virtually, Jan. 9 – 12. Matthew Roden, PhD, President and Chief Executive Officer, will deliver a formal presentation on the company’s platform and progress on Wednesday, Jan. 11, 2022 at 9:00 a.m. ET.
About Aktis Oncology
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology’s molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. To learn more about Aktis Oncology, visit www.aktisoncology.com.
Media Contact:
Lissette Steele
Verge Scientific Communications
lsteele@vergscientific.com
202.930.4762 ext. 409